Drug Trial Radar · NCT01125800
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Last checked: Nov 19, 2026Latest source record: Mar 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Feb 2011
Primary completion
Oct 2014
Study completion Oct 2014
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 18, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in children with recurrent or refractory medulloblastoma, or other tumors potentially dependent on Hedgehog signaling pathway. Phase II study is to assess preliminary efficacy in both adult and pediatric patients with recurrent or refractory MB.
Conditions
- Medulloblastoma
- Rhabdomyosarcoma
- Neuroblastoma
- Hepatoblastoma
- Glioma
- Astrocytoma
Interventions
LDE225Drug
LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose-limiting Toxicities (DLT) in Phase ITime frame: Baseline, End of dose escalation part (Day 42)
- Maximum Tolerated Dose (MTD) of Sonidegib for Prolonged UseTime frame: Baseline, End of dose escalation part (Day 42)
- Percentage of Participants With Objective Response Rate (ORR) by TreatmentTime frame: Baseline, Day 28 of Cycle 2, End of treatment (Within 14 days of last dose)
Locations
14 sites in 6 countries. Site status is shown where the registry gives one.
Children's Healthcare of Atlanta Childern Hosp - ATL
Atlanta, Georgia
Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. John Hopkins
Baltimore, Maryland
Dana Farber Cancer Institute DFCI (3)
Boston, Massachusetts
Seattle Children's Hospital CPKC412A2114
Seattle, Washington
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Bologna, BO, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Newcastle upon Tyne, United Kingdom
Novartis Investigative Site
Sutton, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.